<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "4: As of December ", fill: "#7b3f00"},
{source: "4: As of December ", target: "4: accumulated deficit", fill: "#7b3f00"},
{source: "4: As of December ", target: "7: generate significant revenue", fill: "#d1e231"},
{source: "7: generate significant revenue", target: "7: development programs", fill: "#d1e231"},
{source: "7: development programs", target: "7: profitability", fill: "#d1e231"},
{source: "7: generate significant revenue", target: "9: genetic risk assessment tests", fill: "#006b3c"},
{source: "9: genetic risk assessment tests", target: "10: genetic risk assessment tests", fill: "#ffff31"},
{source: "10: genetic risk assessment tests", target: "10: early stage", fill: "#ffff31"},
{source: "10: early stage", target: "10: development", fill: "#ffff31"},
{source: "10: genetic risk assessment tests", target: "19: competition", fill: "#ffbf00"},
{source: "19: competition", target: "19: personalized health", fill: "#ffbf00"},
{source: "19: personalized health", target: "19: well defined due", fill: "#ffbf00"},
{source: "19: well defined due", target: "19: established market", fill: "#ffbf00"},
{source: "19: established market", target: "19: customer base", fill: "#ffbf00"},
{source: "19: competition", target: "33: generating sufficient cash", fill: "#ffb300"},
{source: "33: generating sufficient cash", target: "33: cannot raise additional capital prior", fill: "#ffb300"},
{source: "33: cannot raise additional capital prior", target: "33: operations", fill: "#ffb300"},
{source: "33: operations", target: "33: strategic alternatives", fill: "#ffb300"},
{source: "33: generating sufficient cash", target: "36: Additional ", fill: "#0c9"},
{source: "36: Additional ", target: "36: financing may", fill: "#0c9"},
{source: "36: financing may", target: "36: available on", fill: "#0c9"},
{source: "36: Additional ", target: "39: As of December ", fill: "#087830"},
{source: "39: As of December ", target: "39: single stockholder", fill: "#087830"},
{source: "39: single stockholder", target: "39: outstanding common stock", fill: "#087830"},
{source: "39: As of December ", target: "40: Accordingly ", fill: "#66424d"},
{source: "40: Accordingly ", target: "40: stockholder may", fill: "#66424d"},
{source: "40: stockholder may", target: "40: stockholder votes", fill: "#66424d"},
{source: "40: stockholder votes", target: "40: votes concerning", fill: "#66424d"},
{source: "40: votes concerning", target: "40: directors", fill: "#66424d"},
{source: "40: directors", target: "40: amendment", fill: "#66424d"},
{source: "40: amendment", target: "40: Certificate of Incorporation or ByLaws ", fill: "#66424d"},
{source: "40: Certificate of Incorporation or ByLaws ", target: "40: significant", fill: "#66424d"},
{source: "40: significant", target: "40: transactions", fill: "#66424d"},
{source: "40: transactions", target: "40: substantially", fill: "#66424d"},
{source: "40: Accordingly ", target: "42: ownership concentration may also adversely", fill: "#de5d83"},
{source: "42: ownership concentration may also adversely", target: "42: market price", fill: "#de5d83"},
{source: "42: market price", target: "42: common stock", fill: "#de5d83"},
{source: "42: ownership concentration may also adversely", target: "47: distribution with certain exceptions", fill: "#0c9"},
{source: "47: distribution with certain exceptions", target: "47: indebtedness issued by", fill: "#0c9"},
{source: "47: indebtedness issued by", target: "47: persons assets excluding cash dividends", fill: "#0c9"},
{source: "47: persons assets excluding cash dividends", target: "47: such securities", fill: "#0c9"},
{source: "47: such securities", target: "47: indebtedness then", fill: "#0c9"},
{source: "47: indebtedness then", target: "47: Series A Preferred Stock ", fill: "#0c9"},
{source: "47: Series A Preferred Stock ", target: "47: proportionate", fill: "#0c9"},
{source: "47: proportionate", target: "47: such distribution", fill: "#0c9"},
{source: "47: such distribution", target: "47: common stock into which", fill: "#0c9"},
{source: "47: common stock into which", target: "47: respective shares", fill: "#0c9"},
{source: "47: respective shares", target: "47: Series A Preferred Stock ", fill: "#0c9"},
{source: "47: Series A Preferred Stock ", target: "47: convertible as", fill: "#0c9"},
{source: "47: convertible as", target: "47: record date", fill: "#0c9"},
{source: "47: record date", target: "47: determination", fill: "#0c9"},
{source: "47: determination", target: "47: common stock entitled", fill: "#0c9"},
{source: "47: distribution with certain exceptions", target: "95: prohibited from fully using", fill: "#ecd540"},
{source: "95: prohibited from fully using", target: "95: loss carryforwards", fill: "#ecd540"},
{source: "95: loss carryforwards", target: "95: which could affect", fill: "#ecd540"},
{source: "95: which could affect", target: "95: financial performance", fill: "#ecd540"},
{source: "95: prohibited from fully using", target: "START_HERE", fill: "#ecd540"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Economic</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Equity_(finance)">Equity (finance)</a></td>
      <td>In finance, equity is ownership of assets that may have debts or other liabilities attached to them. Equity is measured for accounting purposes by subtracting liabilities from the value of the assets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_Nations_Development_Programme">United Nations Development Programme</a></td>
      <td>The United Nations Development Programme (UNDP) is a United Nations organization tasked with helping countries eliminate poverty and achieve sustainable economic growth and human development. Headquartered in New York City, it is the largest UN development aid agency, with offices in 170 countries.The UNDP emphasizes developing local capacity towards long-term self-sufficiency and prosperity.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Programming_tool">Programming tool</a></td>
      <td>A programming tool or software development tool is a computer program that software developers use to create, debug, maintain, or otherwise support other programs and applications. The term usually refers to relatively simple programs, that can be combined to accomplish a task, much as one might use multiple hands to fix a physical object.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ECrew_Development_Program">ECrew Development Program</a></td>
      <td>eCrew Development Program (eCDP, Japanese: クルトレ eCDP), known unofficially as the McDonald's Training Game, is an educational video game created by McDonald's. Released for the Nintendo DS sometime in 2010 internally within the Japanese division of McDonald's, it was only ever distributed to the company's own restaurants domestically, and never meant to be released to the public.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Professional_development">Professional development</a></td>
      <td>Professional development is learning to earn or maintain professional credentials such as academic degrees to formal coursework, attending conferences, and informal learning opportunities situated in practice. It has been described as intensive and collaborative, ideally incorporating an evaluative stage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Risk_assessment">Risk assessment</a></td>
      <td>Broadly speaking, a risk assessment is the combined effort of:\n\nidentifying and analyzing potential (future) events that may negatively impact individuals, assets, and/or the environment (i.e. hazard analysis); and\nmaking judgments "on the tolerability of the risk on the basis of a risk analysis" while considering influencing factors (i.e.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Genetic_engineering">Genetic engineering</a></td>
      <td>Genetic engineering, also called genetic modification or genetic manipulation, is the direct manipulation of an organism's genes using biotechnology. It is a set of technologies used to change the genetic makeup of cells, including the transfer of genes within and across species boundaries to produce improved or novel organisms.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_testing">Prenatal testing</a></td>
      <td>Prenatal testing consists of prenatal screening and prenatal diagnosis, which are aspects of prenatal care that focus on detecting problems with the pregnancy as early as possible. These may be anatomic and physiologic problems with the health of the zygote, embryo, or fetus, either before gestation even starts (as in preimplantation genetic diagnosis) or as early in gestation as practicable.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Genetically_modified_food">Genetically modified food</a></td>
      <td>Genetically modified foods (GM foods), also known as genetically engineered foods (GE foods), or bioengineered foods are foods produced from organisms that have had changes introduced into their DNA using the methods of genetic engineering. Genetic engineering techniques allow for the introduction of new traits as well as greater control over traits when compared to previous methods, such as selective breeding and mutation breeding.The discovery of DNA and the improvement of genetic technology in the 20th century played a crucial role in the development of transgenic technology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Child_development">Child development</a></td>
      <td>Child development involves the biological, psychological and emotional changes that occur in human beings between birth and the conclusion of adolescence. Childhood is divided into 3 stages of life which include early childhood, middle childhood, late childhood ( preadolescence).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preferred_stock">Preferred stock</a></td>
      <td>Preferred stock (also called preferred shares, preference shares, or simply preferreds) is a component of share capital that may have any combination of features not possessed by common stock, including properties of both an equity and a debt instrument, and is generally considered a hybrid instrument. Preferred stocks are senior (i.e., higher ranking) to common stock but subordinate to bonds in terms of claim (or rights to their share of the assets of the company, given that such assets are payable to the returnee stock bond) and may have priority over common stock (ordinary shares) in the payment of dividends and upon liquidation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Additional_Mathematics">Additional Mathematics</a></td>
      <td>Additional Mathematics is a qualification in mathematics, commonly taken by students in high-school (or GCSE exam takers in the United Kingdom). It is applied to a range of problems set out in a different format and wider content to the standard Mathematics at the same level.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Additional_director_general_of_police">Additional director general of police</a></td>
      <td>Additional Director General of Police (ADGP) is an Indian Police Service rank. Though having the maximum possible 3-star police rank just like Director General of Police,  ADGP's are considered same to DGP's.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Superintendent_of_police_(India)">Superintendent of police (India)</a></td>
      <td>Superintendent of police or SP is a senior rank in Indian Police Service or IPS. Superintendent of Police in Hindi means पुलिस अधीक्षक. They have one Star and one Ashoka emblem on their shoulders and below IPS is written.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Additional_member_system">Additional member system</a></td>
      <td>The additional member system (AMS) is a mixed electoral system under which most representatives are elected in single-member districts (SMDs), and the other "additional members" are elected to make the seat distribution in the chamber more proportional to the way votes are cast for party lists. It is distinct from parallel voting (also known as the supplementary member system) in that the "additional member" seats are awarded to parties taking into account seats won in SMDs (referred to as compensation or "top-up"), which is not done under parallel voting (a non-compensatory method).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Order_of_Australia">Order of Australia</a></td>
      <td>The Order of Australia is an honour that recognises Australian citizens and other persons for outstanding achievement and service. It was established on 14 February 1975 by Elizabeth II, Queen of Australia, on the advice of the Australian Government.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Additionality">Additionality</a></td>
      <td>Additionality is the property of an activity being additional by adding something new to the context. It is a determination of whether an intervention has an effect when  compared to a baseline.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Additional_secretary_to_the_Government_of_India">Additional secretary to the Government of India</a></td>
      <td>Additional Secretary (often abbreviated as AS, GoI or Union Additional Secretary or Additional Secretary to Government of India) is a post and a rank under the Central Staffing Scheme of the Government of India. The authority for creation of this post solely rests with Cabinet of India.Additional secretary is mostly a career civil servant, generally from the Indian Administrative Service, and is a government official of high seniority.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Board_of_directors">Board of directors</a></td>
      <td>A board of directors (commonly referred simply as the board) is an executive committee that jointly supervises the activities of an organization, which can be either a for-profit or a nonprofit organization such as a business, nonprofit organization, or a government agency. \nThe powers, duties, and responsibilities of a board of directors are determined by government regulations (including the jurisdiction's corporate law) and the organization's own constitution and by-laws.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock_dividend">Common stock dividend</a></td>
      <td>A common stock dividend is the dividend paid to common stock owners from the profits of the company.  Like other dividends, the payout is in the form of either cash or stock.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Stock_Exchange">New York Stock Exchange</a></td>
      <td>The New York Stock Exchange (NYSE, nicknamed "The Big Board") is an American stock exchange in the Financial District of Lower Manhattan in New York City. It is by far the world's largest stock exchange by market capitalization of its listed companies at US$30.1 trillion as of February 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Convertible_bond">Convertible bond</a></td>
      <td>In finance, a convertible bond or  convertible note or convertible debt (or a convertible debenture if it has a maturity of greater than 10 years) is a type of bond that the holder can convert into a specified number of shares of common stock in the issuing company or cash of equal value.  It is a hybrid security with debt- and equity-like features.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cancellation_of_Debt_Income">Cancellation of Debt Income</a></td>
      <td>Taxpayers in the United States may have tax consequences when debt is cancelled. This is commonly known as COD (Cancellation of Debt) Income.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Net_operating_loss">Net operating loss</a></td>
      <td>Under U.S. Federal income tax law, a net operating loss (NOL) occurs when certain tax-deductible expenses exceed taxable revenues for a taxable year. If a taxpayer is taxed during profitable periods without receiving any tax relief (e.g., a refund) during periods of NOLs, an unbalanced tax burden results.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Hedge_fund">Hedge fund</a></td>
      <td>A hedge fund is a pooled investment fund that trades in relatively liquid assets and is able to make extensive use of more complex trading, portfolio-construction, and risk management techniques in an attempt to improve performance, such as short selling, leverage, and derivatives. Financial regulators generally restrict hedge fund marketing to institutional investors, high net worth individuals, and others who are considered sufficiently sophisticated.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>We have experienced <font color="blue">significant</font> operating losses since our inception and     expect these losses to continue for some time</td>
    </tr>
    <tr>
      <td>We incurred losses from     <font color="blue">operations</font> of dlra5dtta9 million in 2003, dlra6dtta7 million in 2004 and dlra6dtta1 million in     2005</td>
    </tr>
    <tr>
      <td><font color="blue">As of December </font>31, 2005, our <font color="blue">accumulated deficit</font> was dlra61dtta2 million</td>
    </tr>
    <tr>
      <td>Our losses result <font color="blue">primarily from research</font> and <font color="blue">development</font>, general and     <font color="blue"><font color="blue">administrative</font> expenses</font></td>
    </tr>
    <tr>
      <td>We have not generated, and we <font color="blue">may never generate</font>     <font color="blue">sufficient revenue from product sales</font> to cover our operating expenses</td>
    </tr>
    <tr>
      <td>We     will need to generate <font color="blue">significant</font> revenue to continue our research and     <font color="blue"><font color="blue">development</font> programs</font> and achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> when, if     ever, we will achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>The market for <font color="blue"><font color="blue">genetic risk</font> <font color="blue"><font color="blue">assessment</font> tests</font></font> is unproven</td>
    </tr>
    <tr>
      <td>The  market  for <font color="blue"><font color="blue">genetic risk</font> <font color="blue"><font color="blue">assessment</font> tests</font></font> is at an <font color="blue">early stage</font> of     <font color="blue">development</font> and may not continue to grow</td>
    </tr>
    <tr>
      <td>The <font color="blue">general scientific community</font>,     including us, has only a limited understanding of the role of genes in     <font color="blue">predicting disease</font></td>
    </tr>
    <tr>
      <td>When we identify a gene or <font color="blue">genetic marker</font> that may     influence  risk for disease, we <font color="blue">conduct <font color="blue">clinical trials</font></font> to confirm the     <font color="blue">initial scientific discovery</font> and to establish the scientific discovery’s     <font color="blue">clinical utility</font> in the marketplace</td>
    </tr>
    <tr>
      <td>The results of these <font color="blue">clinical trials</font>     <font color="blue">could limit</font> or delay our ability to bring the test to market, reduce the     test’s <font color="blue">acceptance</font> by our customers or cause us to cancel the program, any of     which  would  limit  or  delay  sales and cause <font color="blue"><font color="blue">additional</font> losses</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">marketplace may never accept</font> our products, and we may never be able to sell     our  products  at  a  profit</td>
    </tr>
    <tr>
      <td>We  may  not complete <font color="blue">development</font> of or     <font color="blue">commercialize</font> our other <font color="blue"><font color="blue">genetic risk</font> <font color="blue"><font color="blue">assessment</font> tests</font></font></td>
    </tr>
    <tr>
      <td>The success of our <font color="blue"><font color="blue">genetic risk</font> <font color="blue"><font color="blue">assessment</font> tests</font></font> will depend upon their     <font color="blue"><font color="blue">acceptance</font> as medically useful</font> and cost-<font color="blue">effective</font> by patients, physicians,     dentists,  other  members  of  the medical and <font color="blue">dental community</font> and by     third-party payers, such as insurance companies and the <font color="blue">government</font></td>
    </tr>
    <tr>
      <td>We can     achieve <font color="blue">broad market <font color="blue">acceptance</font> only with</font> substantial <font color="blue">education about</font> the     benefits and <font color="blue">limitations</font> of <font color="blue"><font color="blue">genetic risk</font> <font color="blue"><font color="blue">assessment</font> tests</font></font></td>
    </tr>
    <tr>
      <td>The market for <font color="blue">personalized health</font> is unproven</td>
    </tr>
    <tr>
      <td>The <font color="blue">competition</font> in the field of <font color="blue">personalized health</font> is not <font color="blue">well defined due</font>     to a lack of an <font color="blue">established market</font> and <font color="blue">customer base</font></td>
    </tr>
    <tr>
      <td>The concept is new and     requires consumers to do things differently, hence may be considered a     “<font color="blue">disruptive <font color="blue">technology</font></font>”</td>
    </tr>
    <tr>
      <td><font color="blue">Adoption </font>of such <font color="blue">technology</font> requires substantial     market <font color="blue">development</font></td>
    </tr>
    <tr>
      <td><font color="blue">Activities </font>in these areas remain small and the overall     market is unproven</td>
    </tr>
    <tr>
      <td>There can be no assurance that these <font color="blue">products will</font> be     <font color="blue">successful upon launch</font> or that they can be <font color="blue">sold at sufficient volume</font> to make     <font color="blue">them profitable</font></td>
    </tr>
    <tr>
      <td>If customers do not accept our tests, or take a longer time     to <font color="blue">accept them than</font> we anticipate, then it will reduce our anticipated     sales, resulting in <font color="blue"><font color="blue">additional</font> losses</font></td>
    </tr>
    <tr>
      <td>We  rely  heavily  on  third  parties  to perform sales, marketing and     <font color="blue"><font color="blue">distribution</font> functions on</font> our behalf, which <font color="blue">could limit</font> our efforts to     <font color="blue"><font color="blue"><font color="blue">successfully</font> market</font> products</font></td>
    </tr>
    <tr>
      <td>We have limited experience and <font color="blue">capabilities with respect</font> to <font color="blue">distributing</font>,     marketing and selling <font color="blue"><font color="blue">genetic risk</font> <font color="blue"><font color="blue">assessment</font> tests</font></font></td>
    </tr>
    <tr>
      <td>We have relied and plan     to continue to rely <font color="blue">significant</font>ly on sales, marketing and <font color="blue">distribution</font>     <font color="blue">arrangements</font> with <font color="blue">third parties</font>, over which we have limited influence</td>
    </tr>
    <tr>
      <td>If     these <font color="blue">third parties</font> do not <font color="blue"><font color="blue">successfully</font> market</font> our products, it will reduce     our anticipated sales and increase our losses</td>
    </tr>
    <tr>
      <td>If we are unable to negotiate     acceptable marketing and <font color="blue">distribution</font> <font color="blue">agreements</font> with future <font color="blue">third parties</font>,     or if in the future we elect to perform sales, marketing and <font color="blue">distribution</font>     <font color="blue">functions ourselves</font>, we will incur <font color="blue">significant</font> costs and face a number of     <font color="blue"><font color="blue">additional</font> risks</font>, including the need to recruit experienced marketing and     sales  personnel</td>
    </tr>
    <tr>
      <td><font color="blue">While Alticor </font>has far more experience and success in     marketing, selling and <font color="blue">distributing</font> products than we do, we are <font color="blue">dependent</font>     upon their success, and their failure to <font color="blue"><font color="blue">successfully</font> market</font> our products     <font color="blue">could reduce</font> our anticipated sales and increase our losses</td>
    </tr>
    <tr>
      <td>17     ______________________________________________________________________       If we fail to obtain <font color="blue"><font color="blue">additional</font> capital</font>, or obtain it <font color="blue">on unfavorable terms</font>,     then we may have to end our research and <font color="blue"><font color="blue">development</font> programs</font> and other     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We expect that our current and anticipated <font color="blue">financial resources</font> are adequate     to maintain our current and planned <font color="blue">operations</font> through mid-2007</td>
    </tr>
    <tr>
      <td>If we are     not <font color="blue">generating sufficient cash</font> or cannot raise <font color="blue"><font color="blue">additional</font> capital</font> prior to     that date, we will be unable to fund our business <font color="blue">operations</font> and will be     required to seek other <font color="blue">strategic alternatives</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future capital</font> needs <font color="blue">depend on</font> many factors</td>
    </tr>
    <tr>
      <td>We will need capital for     the <font color="blue">commercial launch</font> of <font color="blue">additional</font> <font color="blue">genetic tests</font>, continued research and     <font color="blue">development</font> efforts, obtaining and <font color="blue">protecting patents</font> and <font color="blue">administrative</font>     expenses</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font><font color="blue">financing may</font> not be available when needed, or, if     available, it may not be <font color="blue">available on</font> favorable terms</td>
    </tr>
    <tr>
      <td>If we cannot obtain     <font color="blue">additional</font>  funding  on  acceptable  terms when needed, we may have to     <font color="blue">discontinue</font>  <font color="blue">operations</font>,  or, at a minimum, curtail one or more of our     research and <font color="blue"><font color="blue">development</font> programs</font></td>
    </tr>
    <tr>
      <td>Because a single <font color="blue">shareholder</font> has a <font color="blue">controlling</font> percentage of our voting     power, other <font color="blue">stockholders</font>’ voting power is limited</td>
    </tr>
    <tr>
      <td><font color="blue">As of December </font>31, 2005, a <font color="blue">single stockholder</font> owned, or had rights to own     <font color="blue">approximately</font> 57dtta4prca of our <font color="blue">outstanding <font color="blue">common stock</font></font></td>
    </tr>
    <tr>
      <td>Accordingly, this     <font color="blue">stockholder may</font> be able to determine the outcome of <font color="blue">stockholder votes</font>,     including  <font color="blue">votes concerning</font> the election of <font color="blue">directors</font>, the adoption or     <font color="blue">amendment</font> of provisions in our Certificate of Incorporation or By-Laws and     the  approval  of  certain  mergers  and  other  <font color="blue">significant</font> corporate     <font color="blue">transactions</font>, including a sale of <font color="blue">substantially</font> all of our assets</td>
    </tr>
    <tr>
      <td><font color="blue">This     </font><font color="blue">stockholder may</font> make <font color="blue">decisions</font> that are adverse to other <font color="blue">stockholders</font>’ or     warrantholders’ interests</td>
    </tr>
    <tr>
      <td>This <font color="blue">ownership concentration may also adversely</font>     affect the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Three of our four <font color="blue">directors</font> are     <font color="blue">individuals</font> chosen by this <font color="blue">single stockholder</font> and that stockholder has the     right  to  choose an <font color="blue">additional</font> director</td>
    </tr>
    <tr>
      <td>These <font color="blue">directors</font> might pursue     policies in the interest of this <font color="blue">single stockholder</font> to the detriment of our     other <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td><font color="blue">The <font color="blue">Series A Preferred Stock </font></font>has <font color="blue">certain rights which</font> are senior to common     <font color="blue">shareholder</font> rights and this may reduce the value of the <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The Series A Preferred Stock, which was issued to <font color="blue">Alticor in March </font>2003,     <font color="blue">accrues dividends at</font> the rate of 8prca of the <font color="blue">original purchase price per year</font>,     <font color="blue">payable only</font> when, as and if declared by the <font color="blue">Board of <font color="blue">Directors </font></font>and are     non-cumulative</td>
    </tr>
    <tr>
      <td>If we declare a <font color="blue">distribution</font>, with certain exceptions,     payable in securities of other persons, evidences of <font color="blue">indebtedness issued by</font>     us or other persons, assets (excluding cash dividends) or options or rights     to purchase any <font color="blue">such securities</font> or evidences of indebtedness, then, in each     such case the holders of the <font color="blue">Series A Preferred Stock </font>shall be entitled to a     <font color="blue">proportionate</font> share of any such <font color="blue">distribution</font> as though the holders of the     <font color="blue">Series A Preferred Stock </font>were the holders of the number of shares of our     <font color="blue">common stock</font> into which their <font color="blue">respective shares</font> of <font color="blue">Series A Preferred Stock </font>    are <font color="blue">convertible as</font> of the <font color="blue">record date</font> fixed for the <font color="blue">determination</font> of the     holders of our <font color="blue">common stock</font> entitled to receive such <font color="blue">distribution</font></td>
    </tr>
    <tr>
      <td>In the event of any liquidation, dissolution or <font color="blue">winding up</font> of the Company,     <font color="blue">whether voluntary</font> or <font color="blue">involuntary</font>, the holders of the Series A Preferred     Stock  shall  be  entitled  to receive, prior and in preference to any     <font color="blue">distribution</font> of any of our assets or <font color="blue">surplus funds</font> to the holders of our     <font color="blue">common stock</font> by reason of their <font color="blue">ownership thereof</font>, the amount of two times     the then-<font color="blue">effective</font> purchase price per share, as adjusted for any stock     dividends, combinations or <font color="blue">splits with respect</font> to such shares, plus all     declared <font color="blue">but unpaid <font color="blue">dividends on</font> such</font> share for each share of Series A     Preferred Stock then held by them</td>
    </tr>
    <tr>
      <td>After receiving this amount, the holders     of the <font color="blue">Series A Preferred Stock </font><font color="blue">shall participate on</font> an as-converted basis     with the holders of <font color="blue">common stock</font> in any of our <font color="blue">remaining assets</font></td>
    </tr>
    <tr>
      <td>18     ______________________________________________________________________       The <font color="blue">preferential treatment accorded</font> the <font color="blue">Series A Preferred Stock </font>might     reduce the value of the <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>If we are <font color="blue">unsuccessful</font> in establishing <font color="blue">additional</font> <font color="blue">strategic alliances</font>, our     ability to develop and <font color="blue">market products</font> and <font color="blue">services may</font> be damaged</td>
    </tr>
    <tr>
      <td>Entering <font color="blue">into <font color="blue">strategic alliances</font></font> for the <font color="blue">development</font> and <font color="blue">commercialization</font>     of products and <font color="blue">services based on</font> our <font color="blue">discoveries</font> is an important element of     our business strategy</td>
    </tr>
    <tr>
      <td>We anticipate entering into <font color="blue">additional</font> collaborative     <font color="blue">arrangements</font>  with  <font color="blue">Alticor  </font>and  other parties in the future</td>
    </tr>
    <tr>
      <td>We face     <font color="blue">significant</font> <font color="blue">competition</font> in <font color="blue">seeking appropriate <font color="blue">collaborators</font></font></td>
    </tr>
    <tr>
      <td>In addition,     these alliance <font color="blue">arrangements</font> are complex to negotiate and time-consuming to     document</td>
    </tr>
    <tr>
      <td>If we fail to maintain <font color="blue">existing alliances</font> or establish <font color="blue">additional</font>     <font color="blue">strategic alliances</font> or other alternative <font color="blue">arrangements</font>, then our ability to     develop and <font color="blue">market products</font> and <font color="blue">services may</font> be damaged</td>
    </tr>
    <tr>
      <td>In addition, the     terms of any future <font color="blue">strategic alliances</font> may be unfavorable to us or these     <font color="blue">strategic alliances</font> may be <font color="blue">unsuccessful</font></td>
    </tr>
    <tr>
      <td>If we fail to obtain an <font color="blue">adequate level</font> of <font color="blue">reimbursement</font> for our products or     services by third-party payers, then our products and <font color="blue">services may</font> not be     <font color="blue">commercially viable</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">availability</font> and levels of <font color="blue">reimbursement</font> by <font color="blue">government</font>al and other     third-party payers affects the market for any <font color="blue">healthcare service</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>third-party payers continually attempt to contain or reduce the costs of     healthcare  <font color="blue">by challenging</font> the <font color="blue">prices charged</font> for <font color="blue">medical products</font> and     services</td>
    </tr>
    <tr>
      <td>Should we enter the <font color="blue">medical channel</font>, our ability to <font color="blue">successfully</font>     <font color="blue">commercialize</font> our <font color="blue">existing <font color="blue">genetic risk</font> <font color="blue">assessment</font> test</font> and others that we     may develop <font color="blue">depends on</font> obtaining adequate <font color="blue">reimbursement</font> from third-party     payers</td>
    </tr>
    <tr>
      <td>The extent of third-party payer <font color="blue">reimbursement</font> may likely heavily     <font color="blue">influence physicians</font>’ and dentists’ <font color="blue">decisions</font> to <font color="blue">recommend <font color="blue">genetic risk</font></font>     <font color="blue"><font color="blue">assessment</font> tests</font>, as well as patients’ elections to <font color="blue">pursue testing</font></td>
    </tr>
    <tr>
      <td>If     <font color="blue">reimbursement</font> is unavailable or limited in scope or amount, then we may not     be  able  sell  our  products and <font color="blue">services at</font> a profit</td>
    </tr>
    <tr>
      <td>In particular,     third-party  <font color="blue">payers tend</font> to deny <font color="blue">reimbursement</font> for <font color="blue">services which</font> they     determine  to be <font color="blue">investigational</font> in nature or which are not considered     “reasonable  and  <font color="blue">necessary</font>”  for <font color="blue">diagnosis</font> or treatment</td>
    </tr>
    <tr>
      <td>To date, few     third-party  payers have agreed to <font color="blue">reimburse patients</font> for <font color="blue">genetic risk</font>     <font color="blue"><font color="blue">assessment</font> tests</font>, and we do not know if third-party payers will, in the     future, provide full <font color="blue">reimbursement</font> coverage for these <font color="blue">genetic tests</font></td>
    </tr>
    <tr>
      <td>If     third-party payers do not provide adequate <font color="blue">reimbursement</font> coverage, then     <font color="blue">individuals</font> may choose to <font color="blue">directly pay</font> for the test</td>
    </tr>
    <tr>
      <td>If both third-party     payers and <font color="blue">individuals</font> are unwilling to pay for the tests, then the number     of tests we can sell may be <font color="blue">significant</font>ly decreased, resulting in reduced     anticipated sales and <font color="blue"><font color="blue">additional</font> losses</font></td>
    </tr>
    <tr>
      <td>If we fail to obtain <font color="blue">patent protection</font> for our products and preserve our     <font color="blue">trade secrets</font>, then <font color="blue"><font color="blue">competitors</font> may</font> develop <font color="blue">competing products</font> and services,     <font color="blue">which will likely decrease</font> our sales and market share</td>
    </tr>
    <tr>
      <td>Our success will partly <font color="blue">depend on</font> our ability to obtain <font color="blue">patent protection</font>,     in the <font color="blue">United States </font>and in other countries, for our products and services</td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">success will also depend upon</font> our ability to preserve our     <font color="blue">trade secrets</font> and to operate <font color="blue">without infringing upon</font> the <font color="blue"><font color="blue">proprietary</font> rights</font>     of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>We own rights in <font color="blue">twenty issued</font> US patents and have a number of <font color="blue">additional</font>     US <font color="blue"><font color="blue">patent <font color="blue">applications</font></font> pending</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">also been granted</font> a number of     <font color="blue">corresponding foreign patents</font> and have a number of <font color="blue">foreign counterparts</font> of     our US patents and <font color="blue"><font color="blue">patent <font color="blue">applications</font></font> pending</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">patent positions</font>, and     those of other <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> companies, are <font color="blue">generally</font>     uncertain and involve complex legal, scientific and factual questions</td>
    </tr>
    <tr>
      <td>Our     ability to develop and <font color="blue">commercialize</font> products and services <font color="blue">depends on</font> our     ability to:       ·                     Obtain patents;       ·                     Obtain licenses to the <font color="blue"><font color="blue">proprietary</font> rights</font> of others;       19     ______________________________________________________________________       ·                     Prevent <font color="blue">others from infringing on</font> our <font color="blue">proprietary</font>     rights; and       ·                     Protect <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">pending <font color="blue">patent <font color="blue">applications</font></font> may</font> not result in <font color="blue">issued patents</font> and any     <font color="blue">issued patents</font> may never afford meaningful protection for our <font color="blue">technology</font> or     products</td>
    </tr>
    <tr>
      <td>Further, <font color="blue">others may</font> develop <font color="blue">competing products</font>, which avoid     <font color="blue">legally infringing upon</font>, or <font color="blue">conflicting with</font>, our patents</td>
    </tr>
    <tr>
      <td>In addition,     <font color="blue"><font color="blue"><font color="blue">competitors</font> may</font> challenge</font> any <font color="blue">patents issued</font> to us, and these <font color="blue">patents may</font>     <font color="blue">subsequently</font> be narrowed, invalidated or <font color="blue">circumvented</font></td>
    </tr>
    <tr>
      <td>We also rely on <font color="blue">trade secrets</font> and <font color="blue">proprietary</font> know-how that we seek to     protect,  in part, <font color="blue">by <font color="blue">confidentiality</font> <font color="blue">agreements</font></font></td>
    </tr>
    <tr>
      <td>The <font color="blue">third parties</font> we     <font color="blue">contract with may breach</font> these <font color="blue">agreements</font>, and we might not have adequate     remedies for any breach</td>
    </tr>
    <tr>
      <td>Additionally, our <font color="blue"><font color="blue"><font color="blue">competitors</font> may</font> discover</font> or     in<font color="blue">dependent</font>ly develop our <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may</font> own or <font color="blue">control patents</font> or <font color="blue">patent <font color="blue">applications</font></font> and require     us to seek licenses, which could increase our costs or <font color="blue">prevent us from</font>     developing or marketing our products or services</td>
    </tr>
    <tr>
      <td>We may not have <font color="blue">rights under patents</font> or <font color="blue">patent <font color="blue">applications</font></font> that are related     to our current or <font color="blue">proposed products</font></td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may</font> own or control these     patents and <font color="blue">patent <font color="blue">applications</font></font> in the <font color="blue">United States </font>and abroad</td>
    </tr>
    <tr>
      <td>Therefore,     in some cases, to develop or sell any <font color="blue">proposed products</font> or services, with     patent rights controlled by <font color="blue">third parties</font>, our <font color="blue">collaborators</font> or we may seek,     or may be required to seek, licenses under third-party patents and patent     <font color="blue">applications</font></td>
    </tr>
    <tr>
      <td>If this occurs, we may have to <font color="blue">pay license fees</font> or royalties     or both to the licensor</td>
    </tr>
    <tr>
      <td>If licenses are not available to us on acceptable     terms, our <font color="blue">collaborators</font> or we may be <font color="blue">prohibited from</font> developing or selling     our products or services</td>
    </tr>
    <tr>
      <td>If  <font color="blue">third parties</font> believe our products or services infringe upon their     patents, they could bring legal proceedings against us seeking damages or     seeking to enjoin us from testing, manufacturing or marketing our products     or services</td>
    </tr>
    <tr>
      <td>Any <font color="blue">litigation could</font> result in substantial expenses to us and     <font color="blue">significant</font>  diversion  of  attention  by our technical and <font color="blue">management</font>     personnel</td>
    </tr>
    <tr>
      <td>Even if we prevail, the time, cost and diversion of resources of     <font color="blue">patent litigation would likely damage</font> our business</td>
    </tr>
    <tr>
      <td>If the other parties in     any <font color="blue">patent litigation brought against us</font> are successful, in addition to any     <font color="blue">liability</font> for damages, we may have to cease the <font color="blue">infringing activity</font> or     obtain a license</td>
    </tr>
    <tr>
      <td><font color="blue">Technological  </font>changes  may  cause our products and services to become     obsolete</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">competitors</font> may</font> develop risk <font color="blue"><font color="blue">assessment</font> tests</font> that are more <font color="blue">effective</font>     than our <font color="blue">technologies</font> or that make our <font color="blue">technologies</font> obsolete</td>
    </tr>
    <tr>
      <td><font color="blue">Innovations </font>in     the  treatment  of  the  diseases in which we have products or product     <font color="blue">candidates</font> could make our <font color="blue">products obsolete</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">innovations could prevent</font>     <font color="blue">us from selling</font>, and <font color="blue">significant</font>ly reduce or eliminate the markets for, our     products</td>
    </tr>
    <tr>
      <td>We may be <font color="blue">prohibited from</font> fully using our net operating <font color="blue">loss <font color="blue">carryforwards</font></font>,     <font color="blue">which could affect</font> our <font color="blue">financial performance</font></td>
    </tr>
    <tr>
      <td>As a result of the <font color="blue">losses incurred since inception</font>, we have not recorded a     <font color="blue">federal income tax provision</font> and have recorded a <font color="blue">valuation allowance against</font>     all <font color="blue">future tax benefits</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of December </font>31, 2005, we had gross net operating     loss and <font color="blue">research tax</font> credit <font color="blue">carryforwards</font> of <font color="blue">approximately</font> dlra43dtta0 million     and dlra870cmam000, respectively, for federal <font color="blue">income tax purposes</font>, expiring in     <font color="blue">varying amounts through</font> the year 2025</td>
    </tr>
    <tr>
      <td><font color="blue">As of December </font>31, 2005, we had gross     net operating loss and <font color="blue">research tax</font> credit <font color="blue">carryforwards</font> of <font color="blue">approximately</font>     dlra20dtta0 million and dlra330cmam000, respectively, for state <font color="blue">income tax purposes</font>,     expiring in <font color="blue">varying amounts through</font> the year 2010</td>
    </tr>
    <tr>
      <td>Our ability to use these     net operating loss and credit <font color="blue">carryforwards</font> is subject to <font color="blue">restrictions</font>     contained in the <font color="blue">Internal Revenue Code </font><font color="blue">which provide</font> for <font color="blue">limitations</font> on our     <font color="blue">utilization</font> of our net operating loss and credit <font color="blue">carryforwards</font> following a     greater than 50prca ownership change during the       20     ______________________________________________________________________       <font color="blue">prescribed testing period</font></td>
    </tr>
    <tr>
      <td>We have experienced <font color="blue">two such ownership</font> changes</td>
    </tr>
    <tr>
      <td>As a result,     all of our net operating <font color="blue">loss <font color="blue">carryforwards</font></font> are limited in <font color="blue">utilization</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">annual limitation may</font> result in the expiration of the <font color="blue">carryforwards</font> prior to     <font color="blue">utilization</font></td>
    </tr>
    <tr>
      <td>In addition, in order to realize the <font color="blue">future tax benefits</font> of our     net operating loss and tax credit <font color="blue">carryforwards</font>, we <font color="blue">must generate taxable</font>     income, of <font color="blue">which there</font> is no assurance</td>
    </tr>
    <tr>
      <td>We <font color="blue">could become</font> subject to intense <font color="blue">competition</font> from other companies, which     may damage our business</td>
    </tr>
    <tr>
      <td>Our industry is <font color="blue">highly <font color="blue">competitive</font></font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">potential <font color="blue">competitors</font></font> in the United     States  and  abroad  are numerous and include major <font color="blue">pharmaceutical</font> and     <font color="blue">diagnostic</font> companies, specialized bio<font color="blue">technology</font> firms, <font color="blue">universities</font> and     other research <font color="blue">institutions</font></td>
    </tr>
    <tr>
      <td>Many of our <font color="blue">competitors</font> have <font color="blue">considerably</font>     greater <font color="blue">financial resources</font>, research and <font color="blue">development</font> staffs, <font color="blue">facilities</font>,     technical personnel, marketing and other <font color="blue">resources than</font> we do</td>
    </tr>
    <tr>
      <td>Furthermore,     many of these <font color="blue">competitors</font> are more experienced than we are in <font color="blue">discovering</font>,     <font color="blue">commercializing</font> and <font color="blue">marketing products</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">greater resources may allow</font>     our <font color="blue">competitors</font> to <font color="blue">discover important genes</font> or <font color="blue">genetic marker</font>s before we do</td>
    </tr>
    <tr>
      <td>If  we  do  not <font color="blue">discover gene variants</font> that <font color="blue">influence disease risk</font> and     <font color="blue">commercialize</font> these <font color="blue">discoveries</font> before our <font color="blue">competitors</font>, then our ability to     <font color="blue">generate sales</font> and <font color="blue">revenue will</font> be reduced or eliminated, and could make our     <font color="blue">products obsolete</font></td>
    </tr>
    <tr>
      <td>We expect <font color="blue">competition</font> to intensify in our <font color="blue">industry as</font>     <font color="blue">technical advances</font> are made and become more <font color="blue">widely known</font></td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue">government</font> regulation which may <font color="blue">significant</font>ly increase our     costs and <font color="blue">delay <font color="blue">introduction</font></font> of <font color="blue">future products</font></td>
    </tr>
    <tr>
      <td>Changes in existing <font color="blue">regulations</font> at either the state or federal level could     require  advance <font color="blue">regulatory</font> approval of <font color="blue"><font color="blue">genetic risk</font> <font color="blue"><font color="blue">assessment</font> tests</font></font>,     resulting in a substantial <font color="blue">curtailment</font> or <font color="blue">even prohibition</font> of our <font color="blue">activities</font>     without <font color="blue">regulatory</font> approval</td>
    </tr>
    <tr>
      <td>If our <font color="blue">genetic tests</font> ever require <font color="blue">regulatory</font>     approval, on either a state or federal level, then the costs of <font color="blue">introduction</font>     may  increase and marketing and sales of <font color="blue">products may</font> be <font color="blue">significant</font>ly     delayed</td>
    </tr>
    <tr>
      <td>We anticipate that the <font color="blue">testing procedure itself will</font> be performed     primarily  in  our  own genetic testing <font color="blue">laboratory</font>, which currently is     registered and will need to be <font color="blue">certified under</font> the auspices of the Clinical     Laboratory Improvement Act of 1988 (CLIA), <font color="blue">administered by</font> the Health Care     Financing Administration</td>
    </tr>
    <tr>
      <td>We anticipate there will also be <font color="blue">additional</font> state     and  local  <font color="blue">regulations</font> governing the operation of this <font color="blue">laboratory</font></td>
    </tr>
    <tr>
      <td>An     <font color="blue">inability</font> to obtain or maintain our CLIA <font color="blue">certification</font> or any applicable     state or local <font color="blue">certification</font> would reduce our revenue and increase our net     losses</td>
    </tr>
    <tr>
      <td>Although it has not done so, the FDA could assert pre-market review     of <font color="blue">genetic tests</font></td>
    </tr>
    <tr>
      <td>We may be subject to product <font color="blue">liability</font> claims that are costly to defend and     that <font color="blue">could limit</font> our ability to use some <font color="blue">technologies</font> in the future</td>
    </tr>
    <tr>
      <td>The design, <font color="blue">development</font>, manufacture and use of our <font color="blue">genetic risk</font> <font color="blue">assessment</font>     <font color="blue">tests involve</font> an <font color="blue">inherent risk</font> of product <font color="blue">liability</font> claims and associated     <font color="blue">adverse publicity</font></td>
    </tr>
    <tr>
      <td><font color="blue">Producers </font>of <font color="blue">medical products</font> face substantial <font color="blue">liability</font>     for damages in the event of <font color="blue">product failure</font> or <font color="blue">allegations</font> that the product     caused harm</td>
    </tr>
    <tr>
      <td>We currently maintain product <font color="blue">liability</font> insurance, but it is     expensive and <font color="blue">difficult</font> to obtain, may not be available in the future on     <font color="blue">economically</font> acceptable terms and may not be adequate to <font color="blue">fully protect us</font>     against all claims</td>
    </tr>
    <tr>
      <td>We may become subject to product <font color="blue">liability</font> claims that,     even if they are without merit, could result in <font color="blue">significant</font> legal defense     costs</td>
    </tr>
    <tr>
      <td>We could be held liable for damages in excess of the limits of our     <font color="blue">insurance coverage</font>, and any claim or resulting <font color="blue">product recall could</font> create     <font color="blue">significant</font> <font color="blue">adverse publicity</font></td>
    </tr>
    <tr>
      <td>Ethical, legal and <font color="blue">social issues</font> related to <font color="blue">genetic testing may reduce</font>     demand for our products</td>
    </tr>
    <tr>
      <td>Genetic testing has <font color="blue">raised issues</font> regarding the appropriate <font color="blue">utilization</font> and     the <font color="blue">confidentiality</font> of information <font color="blue">provided by genetic testing</font></td>
    </tr>
    <tr>
      <td><font color="blue">Genetic     </font>tests for assessing a person’s likelihood of developing a <font color="blue">chronic disease</font>     have <font color="blue">focused public attention on</font> the need to protect the privacy of genetic     information</td>
    </tr>
    <tr>
      <td>For example, concerns have been expressed that insurance     carriers and <font color="blue">employers may use</font> these tests to       21     ______________________________________________________________________       <font color="blue">discriminate on</font> the basis of genetic information, resulting in barriers to     the  <font color="blue">acceptance</font>  of  genetic  tests  by  consumers</td>
    </tr>
    <tr>
      <td>This could lead to     <font color="blue">government</font>al authorities prohibiting genetic testing or calling for limits     on or regulating the use of genetic testing, particularly for diseases for     <font color="blue">which there</font> is <font color="blue">no known cure</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">dependence on key executives</font> and <font color="blue">scientists could adversely impact</font> the     <font color="blue">development</font> and <font color="blue">management</font> of our business</td>
    </tr>
    <tr>
      <td>Our success <font color="blue">substantially</font> <font color="blue">depends on</font> the ability, experience and performance     of our senior <font color="blue">management</font> and other <font color="blue">key personnel</font></td>
    </tr>
    <tr>
      <td>If we lose one or more of     the members of our senior <font color="blue">management</font> or other <font color="blue">key employees</font>, it could damage     our <font color="blue"><font color="blue">development</font> programs</font> and our business</td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">success depends</font>     on our ability to continue to hire, train, retain and <font color="blue">motivate skilled</font>     managerial and <font color="blue">scientific personnel</font></td>
    </tr>
    <tr>
      <td>The pool of <font color="blue">personnel with</font> the skill     that we require is limited</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>to hire from this limited pool is     intense</td>
    </tr>
    <tr>
      <td>We compete with numerous <font color="blue">pharmaceutical</font> and <font color="blue">healthcare companies</font>,     as well as <font color="blue">universities</font> and <font color="blue">nonprofit research organizations</font> in the highly     <font color="blue">competitive</font> Boston, Massachusetts’s business area</td>
    </tr>
    <tr>
      <td>Philip R Reilly, our Chief Executive Officer, Dr</td>
    </tr>
    <tr>
      <td>Kenneth Kornman, our     President and Chief Scientific Officer, or Dr</td>
    </tr>
    <tr>
      <td>Ramon Mohanlal, our Chief     Medical  Officer, <font color="blue">could delay</font> our research and <font color="blue"><font color="blue">development</font> programs</font> or     <font color="blue">otherwise damage</font> our business</td>
    </tr>
    <tr>
      <td>In March 2003, we <font color="blue">entered into <font color="blue">employment</font></font>     <font color="blue">agreements</font> with three-year terms with Dr</td>
    </tr>
    <tr>
      <td><font color="blue">Reilly and Dr</font></td>
    </tr>
    <tr>
      <td>Each of     these employees can terminate his <font color="blue">employment</font> upon 30 days notice</td>
    </tr>
    <tr>
      <td>We do not     maintain <font color="blue">key man life insurance on</font> any of our personnel</td>
    </tr>
    <tr>
      <td>In a circumstance in which Alticor enters a business in <font color="blue">competition</font> with our     own, our <font color="blue">Directors </font>might have a conflict of interest</td>
    </tr>
    <tr>
      <td>In <font color="blue">conjunction with</font> our <font color="blue">strategic alliance with</font> Alticor, we have agreed to     certain   terms   for  <font color="blue">allocating</font>  <font color="blue">opportunities</font>  as  permitted  under     Section 122(17) of the <font color="blue">Delaware General Corporation Law</font></td>
    </tr>
    <tr>
      <td>This agreement, as     set forth in the Purchase Agreement, regulates and defines the conduct of     certain  of  our  affairs  as they <font color="blue">may involve</font> Alticor as our majority     stockholder  and  its  <font color="blue">affiliates</font>,  and the powers, rights, duties and     <font color="blue">liabilities</font>  of  us  and our officers and <font color="blue">directors</font> in <font color="blue">connection with</font>     corporate <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>Except <font color="blue">under certain <font color="blue">circumstances</font></font>, Alticor and its <font color="blue">affiliates</font> have the     right to engage in the same or similar <font color="blue">activities</font> or lines of business or     have  an  interest  in  the  same  classes  or <font color="blue">categories</font> of corporate     <font color="blue">opportunities</font> as we do</td>
    </tr>
    <tr>
      <td><font color="blue">If Alticor </font>or one of our <font color="blue">directors</font> appointed by     Alticor, and its <font color="blue">affiliates</font> acquire knowledge of a <font color="blue">potential transaction</font> or     matter  that  may  be a <font color="blue">corporate <font color="blue">opportunity</font></font> for both Alticor and its     <font color="blue">affiliates</font> and us, to the <font color="blue">fullest extent permitted by law</font>, Alticor and its     <font color="blue">affiliates</font> will not have a duty to inform us about the <font color="blue">corporate <font color="blue">opportunity</font></font>     or  be  liable  to  us or to you for breach of any <font color="blue">fiduciary duty as</font> a     stockholder of ours for not <font color="blue">informing us</font> of the <font color="blue">corporate <font color="blue">opportunity</font></font>,     keeping it for its own account, or referring it to another person</td>
    </tr>
    <tr>
      <td>Additionally, <font color="blue">except under</font> limited <font color="blue">circumstances</font>, if an officer or employee     of  <font color="blue">Alticor  </font>who  is  also one of our <font color="blue">directors</font> is offered a corporate     <font color="blue">opportunity</font>, such <font color="blue">opportunity</font> shall not belong to us</td>
    </tr>
    <tr>
      <td>In addition, we agreed     that <font color="blue">such director will</font> have satisfied his duties to us and not be liable to     us or to you in <font color="blue">connection with</font> such <font color="blue">opportunity</font></td>
    </tr>
    <tr>
      <td>The terms of this <font color="blue">agreement will terminate on</font> the date that no person who is     a director, officer or employee of ours is also a director, officer, or     employee of Alticor or an affiliate</td>
    </tr>
    <tr>
      <td>We do not expect to <font color="blue">pay dividends</font> for the <font color="blue">foreseeable future</font> and you should     not expect to receive any <font color="blue">funds without selling</font> your shares of <font color="blue">common stock</font>,     which you may only be able to do at a loss</td>
    </tr>
    <tr>
      <td>We have never declared or paid any <font color="blue">cash <font color="blue">dividends on</font></font> our <font color="blue">capital stock</font></td>
    </tr>
    <tr>
      <td>We     currently  intend  to retain any earnings for use in the operation and     expansion of our business and do not anticipate paying any cash       22     ______________________________________________________________________       <font color="blue">dividends on</font> our <font color="blue">common stock</font> in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>Therefore, you     should not expect to receive any <font color="blue">funds without selling</font> your shares, which     you may only be able to do at a loss</td>
    </tr>
  </tbody>
</table>